Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart
failure worldwide, is increasing in prevalence, confers substantial morbidity and mortality …

Cyclic nucleotide phosphodiesterases (PDEs) modulate the neurohormonal regulation of
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …

Cyclic GMP–phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract
maladaptive cardiac changes triggered by diabetes in some but not all studies. We …

Nuclear-and membrane-initiated estrogen signaling cooperate to orchestrate the pleiotropic
effects of estrogens. Classical estrogen receptors (ERs) act transcriptionally and govern the …

Cyclic guanosine monophosphate (cGMP), produced by guanylate cyclase (GC), activates
protein kinase G (PKG) and regulates cardiac remodeling. cGMP/PKG signal is activated by …

Aging is associated with heart and vascular dysfunction that contributes to cardiovascular
disease (CVD) risk. Clinical data support a sexual dimorphism in the time course of aging …

Great progress has been made in the understanding of the pathophysiology of
cardiovascular diseases (CVDs), and this has improved the prevention and prognosis of …

Central obesity with cardiometabolic syndrome (CMS) is a major global contributor to human
disease, and effective therapies are needed. Here, we show that cyclic GMP–selective …

Aims Free fatty acid receptor 4 (Ffar4) is a G-protein-coupled receptor for endogenous
medium-/long-chain fatty acids that attenuates metabolic disease and inflammation …

The definition of heart failure with preserved ejection fraction (HFpEF) has evolved from a
clinically based “diagnosis of exclusion” to definitions focused on objective evidence of …